Predicting allopurinol response in patients with gout

被引:43
|
作者
Wright, Daniel F. B. [1 ]
Duffull, Stephen B. [1 ]
Merriman, Tony R. [2 ]
Dalbeth, Nicola [3 ]
Barclay, Murray L. [4 ,5 ]
Stamp, Lisa K. [4 ]
机构
[1] Univ Otago, Sch Pharm, POB 56, Dunedin 9054, New Zealand
[2] Univ Otago, Dept Biochem, Dunedin 9054, New Zealand
[3] Univ Auckland, Dept Med, Auckland 1, New Zealand
[4] Univ Otago, Dept Med, Christchurch, New Zealand
[5] Christchurch Hosp, Dept Clin Pharmacol, Christchurch, New Zealand
关键词
allopurinol; gout; nonmem; pharmacokinetic-pharmacodynamics; CONTROL SAMPLE SETS; SERUM URIC-ACID; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; VS; SEQUENTIAL-ANALYSIS; HYPERSENSITIVITY SYNDROME; CREATININE CLEARANCE; PLASMA OXYPURINOL; ADVERSE-REACTIONS; HEALTHY-SUBJECTS;
D O I
10.1111/bcp.12799
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AimsThe primary aim of this research was to predict the allopurinol maintenance doses required to achieve the target plasma urate of 0.36mmoll(-1). MethodsA population analysis was conducted in nonmem using oxypurinol and urate plasma concentrations from 133 gout patients. Maintenance dose predictions to achieve the recommended plasma urate target were generated. ResultsThe urate response was best described by a direct effects model. Renal function, diuretic use and body size were found to be significant covariates. Dose requirements increased approximately 2-fold over a 3-fold range of total body weight and were 1.25-2 fold higher in those taking diuretics. Renal function had only a modest impact on dose requirements. ConclusionsContrary to current guidelines, the model predicted that allopurinol dose requirements were determined primarily by differences in body size and diuretic use. A revised guide to the likely allopurinol doses to achieve the target plasma urate concentration is proposed.
引用
收藏
页码:277 / 289
页数:13
相关论文
共 50 条
  • [41] Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout
    Garry G. Graham
    Sophie L. Stocker
    Diluk R.W. Kannangara
    Richard O. Day
    Current Rheumatology Reports, 2018, 20
  • [42] Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients
    Reinders, Mattheus K.
    van Roon, Eric N.
    Houtman, Pieternella M.
    Brouwers, Jacobus R. B. J.
    Jansen, Tim L. Th. A.
    CLINICAL RHEUMATOLOGY, 2007, 26 (09) : 1459 - 1465
  • [43] Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout
    Graham, Garry G.
    Stocker, Sophie L.
    Kannangara, Diluk R. W.
    Day, Richard O.
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (08)
  • [44] Febuxostat versus allopurinol for gout
    Lustberg, ME
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (14): : 1532 - 1532
  • [45] TREATMENT OF GOUT WITH ALLOPURINOL AND SULPHINPYRAZONE IN COMBINATION AND WITH ALLOPURINOL ALONE
    KUZELL, WC
    SEEBACH, LM
    GLOVER, RP
    JACKMAN, AE
    ANNALS OF THE RHEUMATIC DISEASES, 1966, 25 (6S) : 634 - &
  • [46] Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study
    Veenstra, Frouwke
    Wanten, Sophie A. C.
    Verhoef, Lise M.
    ter Stal, Minke
    Kwok, Wing-Yee
    van den Hoogen, Frank H. J.
    Flendrie, Marcel
    van Herwaarden, Noortje
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2021, 5 (01)
  • [47] Allopurinol efficacy in patients with tophus gout and chronic renal failure
    Yakunina, I. A.
    Barskova, V. G.
    Nasonova, V. A.
    TERAPEVTICHESKII ARKHIV, 2006, 78 (06) : 88 - +
  • [48] Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout
    Kim, Seoyoung C.
    Neogi, Tuhina
    Kang, Eun Ha
    Liu, Jun
    Desai, Rishi J.
    Zhang, MaryAnn
    Solomon, Daniel H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (09) : 994 - 1004
  • [49] CArdiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular ComoRbiditiES
    White, William B.
    Chohan, Saima
    Dabholkar, Aruna
    Hunt, Barbara
    Jackson, Robert
    AMERICAN HEART JOURNAL, 2012, 164 (01) : 14 - 20
  • [50] Allopurinol versus febuxostat for gout
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2022, 4 (06): : E393 - E393